Eagle Pharmaceuticals Q2 Adjusted EPS $1.18 Beats $1.05 Estimate, Sales $64.65M Beat $59.35M Estimate
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals (NASDAQ:EGRX) reported Q2 earnings of $1.18 per share, beating the analyst consensus estimate of $1.05 by 12.38%. However, this is a 24.36% decrease from the same period last year. The company also reported quarterly sales of $64.65 million, beating the analyst consensus estimate of $59.35 million by 8.92%, but this is a 12.80% decrease from the same period last year.
August 08, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eagle Pharmaceuticals reported better than expected Q2 earnings and sales, but both figures are down from the same period last year.
While Eagle Pharmaceuticals beat Q2 estimates, the year-on-year decreases in earnings and sales could potentially offset any positive impact from the earnings beat. This could lead to a neutral short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100